Dynavax Technologies Research Development Over Time
| DVAX Stock | USD 12.91 0.25 1.97% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dynavax Technologies Performance and Dynavax Technologies Correlation. Dynavax |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.208 | Earnings Share 0.15 | Revenue Per Share 2 | Quarterly Revenue Growth 0.16 | Return On Assets (0) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Research Development Analysis
Compare Dynavax Technologies and related stocks such as Alkermes Plc, Neurocrine Biosciences, and Intracellular Th Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKS | 20.5 M | 141.9 M | 6.5 M | 128.1 M | 7.8 M | 4 M | 2.3 M | 7.2 M | 68.9 M | 52.8 M | 1.9 M | 1 M | 393.8 M | 270.8 M | 284.3 M |
| NBIX | 12.6 M | 31 M | 37.2 M | 39.2 M | 46.4 M | 81.5 M | 94.3 M | 121.8 M | 160.5 M | 200 M | 275 M | 328.1 M | 463.8 M | 565 M | 593.2 M |
| ITCI | 7.7 M | 7.7 M | 15.5 M | 23 M | 21.2 M | 87.7 M | 93.8 M | 79.4 M | 132.2 M | 89.1 M | 65.8 M | 88.8 M | 134.7 M | 180.1 M | 189.1 M |
| AQST | 1.3 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 22.1 M | 23.1 M | 20.6 M | 19.9 M | 17 M | 17.5 M | 13.1 M | 16.7 M |
| AMPH | 31 M | 31 M | 31.2 M | 33 M | 28.4 M | 37.1 M | 41.2 M | 43.4 M | 57.6 M | 68.9 M | 67.2 M | 60.9 M | 74.8 M | 73.7 M | 54.9 M |
| LNTH | 40.9 M | 40.9 M | 40.6 M | 30.5 M | 13.7 M | 14.4 M | 12.2 M | 18.1 M | 17.1 M | 20 M | 32.8 M | 45 M | 311.7 M | 77.7 M | 57.1 M |
| ANIP | 1.4 M | 44.2 M | 16.9 M | 1.7 M | 2.7 M | 2.9 M | 2.9 M | 9.1 M | 15.4 M | 19.8 M | 16 M | 11.4 M | 22.3 M | 34.3 M | 36 M |
| IRWD | 57.2 M | 86.1 M | 113.5 M | 102.4 M | 101.9 M | 108.7 M | 139.5 M | 148.2 M | 166.5 M | 115 M | 88.1 M | 70.4 M | 44.3 M | 116.1 M | 108.7 M |
| PCRX | 33.2 M | 14.9 M | 9.9 M | 21.6 M | 18.7 M | 28.7 M | 45.7 M | 57.3 M | 55.7 M | 72.1 M | 59.4 M | 55.5 M | 84.8 M | 76.3 M | 46.7 M |
| COLL | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 15 M | 8 M | 14.9 M | 8.6 M | 8.7 M | 10.3 M | 9.8 M | 9.5 M | 4 M | 0.0 | 0.0 |
| EBS | 193 M | 124.8 M | 120.2 M | 119.9 M | 150.8 M | 154 M | 108.3 M | 97.4 M | 142.8 M | 226.2 M | 234.5 M | 234 M | 193 M | 111.4 M | 128.2 M |
| DRRX | 6.4 M | 34.1 M | 20.3 M | 18.9 M | 22.4 M | 24.3 M | 29.3 M | 31.6 M | 25.5 M | 30.2 M | 27.7 M | 31.8 M | 36.9 M | 29.4 M | 30.6 M |
Dynavax Technologies and related stocks such as Alkermes Plc, Neurocrine Biosciences, and Intracellular Th Research Development description
My Equities
My Current Equities and Potential Positions
| Dynavax Technologies | DVAX |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 12.91
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.